How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any equality issues that need special consideration and are not covered in the medical technology consultation document?

  • Question on Document

    Are there any other relevant ongoing studies that address the evidence gaps?

Evidence generation plan

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

5 Minimum evidence standards

Neupulse has some clinical evidence suggesting that it may improve symptoms of tic disorders and Tourette syndrome in young people and adults. The technology did not report any safety concerns when using the digital technology to support treatment of tic disorders and Tourette syndrome.

In addition to the evidence above, the committee has indicated that it may in the future be able to recommend technologies in this topic area that have evidence for: 

  • a beneficial impact of the digital technologies compared with standard care for treating tic disorders and Tourette syndrome without digital technologies 

  • a clinical improvement in tic disorders and Tourette syndrome using the Yale Global Tic Severity Rating Scale total scoring 

  • resource use associated with the technologies and NHS standard care 

  • intervention acceptance, completion rates, patient preference, and uptake rates  

the safe use of the technology (including all adverse events).

The company can strengthen the evidence base by also having evidence for: 

  • effects on health-related quality of life measured through the EQ-5D 

  • effectiveness in different subgroups 

  • where the technology is used in the care pathway.